These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30496460)

  • 1. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
    Deshpande D; Alffenaar JC; Köser CU; Dheda K; Chapagain ML; Simbar N; Schön T; Sturkenboom MGG; McIlleron H; Lee PS; Koeuth T; Mpagama SG; Banu S; Foongladda S; Ogarkov O; Pholwat S; Houpt ER; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S308-S316. PubMed ID: 30496460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant
    Singh S; Gumbo T; Boorgula GD; Thomas TA; Philley JV; Srivastava S
    Antimicrob Agents Chemother; 2024 Feb; 68(2):e0108023. PubMed ID: 38131673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
    van Rijn SP; Srivastava S; Wessels MA; van Soolingen D; Alffenaar JC; Gumbo T
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.
    Alghamdi WA; Alsultan A; Al-Shaer MH; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Schmidt S; Heysell SK; Kempker RR; Cegielski JP; Peloquin CA
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model.
    Srivastava S; Chapagain M; van Zyl J; Deshpande D; Gumbo T
    J Glob Antimicrob Resist; 2021 Mar; 24():403-410. PubMed ID: 33508482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
    Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
    Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.
    Chirehwa MT; Court R; de Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; Warren R; Denti P; McIlleron H
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.
    van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC
    Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-a-week tigecycline for the treatment of drug-resistant TB.
    Deshpande D; Magombedze G; Srivastava S; Bendet P; Lee PS; Cirrincione KN; Martin KR; Dheda K; Gumbo T
    J Antimicrob Chemother; 2019 Jun; 74(6):1607-1617. PubMed ID: 30820554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development of Inhalable d-Cycloserine and Ethionamide To Overcome Pharmacokinetic Interaction and Enhance Efficacy against
    Ranjan R; Srivastava A; Bharti R; Roy T; Verma S; Ray L; Misra A
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.
    Deshpande D; Srivastava S; Bendet P; Martin KR; Cirrincione KN; Lee PS; Pasipanodya JG; Dheda K; Gumbo T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimum inhibitory concentration of cycloserine against Mycobacterium tuberculosis using the MGIT 960 system and a proposed critical concentration.
    Wu X; Shang Y; Ren W; Wang W; Wang Y; Xue Z; Li S; Pang Y
    Int J Infect Dis; 2022 Aug; 121():148-151. PubMed ID: 35577251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.
    Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children.
    Srivastava S; van Zyl J; Cirrincione K; Martin K; Thomas T; Deshpande D; Alffenaar JW; Seddon JA; Gumbo T
    Pediatr Infect Dis J; 2020 Dec; 39(12):1092-1100. PubMed ID: 32773662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.